It has been an honour to serve our Company, China Regenerative Medicine International Limited (“CRMI”), as the Chairman of Board of Directors (the “Board”). We are presented unparalleled opportunities and moving into an important and exciting period in our corporate history.

During the last financial year, CRMI has made significant changes in the senior management team and the Board to respond the new needs for the Company development. Eminent professionals were invited to join the Board to strengthen our profile in international business, corporate strategy, as well as science and technology. A new Chief Executive Officer (“CEO”) was appointed to drive the Company from the phase of research and development (“R&D”) to large scale manufacture, market and sales. Under the strong leadership of our new CEO, a detailed three-year operation plan was proposed, and approved by the Board, and implemented from May 2017. It should be pointed out that this three-year operation plan focused on delivery and financial returns to shareholders.

The performance of our Company, in terms of product sales and financial figures, improved compared to previous years. The significant change in sales represented a clear indication of the Company transformation from R&D to full commercialisation. Our products and services have two important features, heavily regulated and for the unmet clinical needs, both bearing strong social responsibilities. As a public company, we recognise these social responsibilities and the responsibility of financial returns to our shareholders.

We aim at becoming a global leader in regenerative medicine. Our tissue engineered cornea product, “Acornea”, has been reported by major international media including BBC, CBS etc, and attracted global attentions. Our R&D programs including those conducted in the CRMI Technology Centre at the University of Oxford resulted in cutting edge technologies to provide pipeline products for the Company. We seek opportunities for collaborations and expansion in Africa, America, Europe and Far East to enhance our international profile and to increase our market share. As the name indicates, China Regenerative Medicine International is a regenerative medicine company, mainly based in China but serving the international markets.

Finally I would like to thank our friends, who helped CRMI in various ways, our collaborators and partners, who joined us to bring our new products to the patients, and our employees in CRMI and its subsidiaries, without their contributions and dedication none of the achievements was possible.

Professor Zhanfeng Cui, PhD, DSc, FREng
17 July 2017